

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-12. (Canceled)

13. (Currently Amended) A monoclonal antibody that competes with a monoclonal antibody MAb 763-15-5 for specific binding to the human cytochrome p450 2C9 allelic variants 2C9\*1, 2C9\*2, and 2C9\*3 at the same epitope bound by the monoclonal antibody MAb 763-15-5, wherein the MAb 763-15-5 inhibits 2C9\*1 catalyzed metabolism of phenanthrene and 2C9\*2 catalyzed metabolism of phenanthrene, wherein binding between the monoclonal antibody MAb 763-15-5 and the human cytochrome p450 2C9 allelic variants 2C9\*1, 2C9\*2, and 2C9\*3 is detectable by an enzyme-linked immunosorbent assay, and wherein MAb 763-15-5 is produced by the hybridoma cell line deposited as ATCC PTA-1079, and wherein the light chain variable domain comprises the three CDR regions from the light chain of a monoclonal antibody MAb 763-15-5 (ATCC PTA-1079), and the heavy chain variable domain comprises the three CDR regions from the heavy chain of the monoclonal antibody MAb 763-15-5 (ATCC PTA-1079).

14. (Previously Presented) The monoclonal antibody of claim 13 that lacks specific binding to each of human cytochromes P450 1A1, 1A2, 2A6, 2B6, 2C18, 2C19, 2D6, 2E1, 3A4, and 3A5.

15. (Previously Presented) The monoclonal antibody of claim 13 that inhibits the phenanthrene metabolism enzyme activity of human cytochrome P450 allelic variant 2C9\*2 by more than 90%.

16-17. (Canceled)

18. (Previously Presented) The monoclonal antibody of claim 13 that is a Fab fragment.

19. (Previously Presented) The monoclonal antibody of claim 13 that is a mouse antibody.

20. (Previously Presented) A cell line producing the monoclonal antibody of claim 13.

21. (Original) The cell line of claim 20 that is a eucaryotic cell line.

22. (Previously Presented) The cell line of claim 20 that is a procaryotic cell line.

23-24. (Canceled)

25. (Previously Presented) The monoclonal antibody of claim 13 that inhibits the phenanthrene metabolism enzyme activity of human cytochrome P450 allelic variant 2C9\*1 and inhibits the phenanthrene metabolism enzyme activity of human cytochrome P450 allelic variant 2C9\*2.

26. (Currently Amended) The monoclonal antibody of claim 13 that inhibits the phenanthrene metabolism enzyme activity of human cytochrome P450 2C18 by at least 30%.

27-73. (Canceled)

74. (Previously Presented) The monoclonal antibody of claim 13, wherein the monoclonal antibody comprises the monoclonal antibody MAb 763-15-5 (ATCC PTA-1079).

75. (Previously Presented) A monoclonal antibody MAb 763-15-5 which is produced by the hybridoma cell line deposited as ATCC PTA-1079, wherein the monoclonal antibody MAb 763-15-5 specifically binds to the human cytochrome p450 2C9 allelic variants 2C9\*1, 2C9\*2 and 2C9\*3, and binding between the monoclonal antibody MAb 763-15-5 and the human cytochrome p450 2C9 allelic variants 2C9\*1, 2C9\*2, and 2C9\*3 is detectable by an enzyme-linked immunosorbent assay.

76. (Currently Amended) A monoclonal antibody that competes with the monoclonal antibody MAb 763-15-5 of claim 75 for specific binding to the human cytochrome p450 2C9 allelic variants 2C9\*1, 2C9\*2 and 2C9\*3 at the same epitope bound by the monoclonal antibody MAb 763-15-5, that has a light chain variable domain comprising the three CDR regions from the light chain of a monoclonal antibody MAb 763-15-5 (ATCC PTA-1079), and that has a heavy chain variable domain comprising the three CDR regions from the heavy chain of the monoclonal antibody MAb 763-15-5 (ATCC PTA-1079).

77. (Previously Presented) The monoclonal antibody of claim 76, wherein the monoclonal antibody inhibits 2C9 catalyzed metabolism of phenanthrene.

78. (Currently Amended) A monoclonal antibody that competes with the monoclonal antibody MAb 763-15-5 of claim 75 for specific binding to the human cytochrome p450 2C9 allelic variants 2C9\*1, 2C9\*2 and 2C9\*3, wherein the monoclonal antibody inhibits 2C18 catalyzed metabolism of phenanthrene by at least 30%, and wherein the light chain variable domain comprises the three CDR regions from the light chain of a monoclonal antibody MAb 763-15-5 (ATCC PTA-1079), and the heavy chain variable domain comprises the three CDR regions from the heavy chain of the monoclonal antibody MAb 763-15-5 (ATCC PTA-1079).

79. (Canceled)

80. (Previously Presented) The monoclonal antibody of claim 76, wherein the monoclonal antibody inhibits 2C9 catalyzed metabolism of diclofenac.

81. (Previously Presented) The monoclonal antibody of claim 76, wherein the monoclonal antibody inhibits 2C9\*1 catalyzed metabolism of phenanthrene, and inhibits 2C9\*2 catalyzed metabolism of phenanthrene.

82. (Previously Presented) The monoclonal antibody of claim 76, wherein the monoclonal antibody inhibits 2C9\*1 catalyzed metabolism of diclofenac, phenanthrene, or bufuralol, inhibits 2C9\*2 catalyzed metabolism of diclofenac, phenanthrene, or bufuralol, and inhibits 2C9\*3 catalyzed metabolism of diclofenac, phenanthrene, or bufuralol.